Parkinson's Disease Mitochondrial Neuroprotection Companies

Overview

Overview

This category covers biotechnology and pharmaceutical companies developing mitochondrial-targeted neuroprotection therapies for Parkinson's disease. These approaches address the fundamental mitochondrial dysfunction that is a central pathological feature in PD, including Complex I deficiency, impaired mitophagy, oxidative stress, and defective mitochondrial dynamics.

The rationale for mitochondrial-targeted therapies in PD is strong, supported by both genetic evidence (PINK1, PARKIN, DJ-1 mutations causing familial PD) and environmental evidence (MPTP, rotenone, pesticides causing mitochondrial Complex I inhibition and PD-like syndromes)[@schapira2014].

Key Companies

Vandria SA

• Focus: Mitochondrial quality control and mitophagy induction
• Lead Candidate: VNA-100
• Indication: Parkinson's disease
• Stage: Preclinical/IND-enabling
• Mechanism: Mitophagy inducer targeting the PINK1-PARKIN pathway
• Notes: Swiss-based company with dual programs in AD (VNA-318) and PD (VNA-100)
• Page: [Vandria SA](/companies/vandria)

NeuroMito Therapeutics

• Focus: Mitochondrial antioxidants
• Lead Candidate: NMT-101
• Indication: Parkinson's disease
• Stage: Phase 2
• Mechanism: Mitochondria-targeted nitroxide compound (TPP moiety) for selective ROS scavenging
• Notes: Based in Boston, Series C funded in 2025
• Page: [NeuroMito Therapeutics](/companies/Neuromito-therapeutics)

Clene Nanomedicine

• Focus: Catalytic nanotherapeutic approach
• Lead Candidate: CNM-Au8
• Indication: Parkinson's disease (and ALS)
• Stage: Phase 2
• Mechanism: Gold nanocrystals catalyze redox reactions to support mitochondrial function and reduce oxidative stress
• Notes: Oral bioavailability, crosses blood-brain barrier
• Page: [Clene Nanomedicine](/companies/clene-nanomedicine)

Napa Therapeutics

• Focus: Mitochondrial protection
• Lead Candidate: NP-101
• Indication: Parkinson's disease
• Stage: Phase 1
• Mechanism: Mitochondria-targeted therapeutic
• Page: [Napa Therapeutics](/companies/napa-therapeutics)

Mitothera

• Focus: Mitochondrial protectants
• Lead Candidate: MT-101
• Indication: Neurodegeneration (including PD)
• Stage: Preclinical
• Mechanism: CoQ10-based mitochondrial protectant with ubiquinone moiety for direct ROS scavenging
• Page: [Mitothera](/companies/mitothera)

Mechanism Categories

Mitochondrial Antioxidants

Companies developing antioxidants specifically targeted to mitochondria using lipophilic cations (TPP - triphenylphosphonium) that accumulate in the mitochondrial matrix due to the mitochondrial membrane potential:

• NeuroMito Therapeutics (NMT-101): TPP-nitroxide conjugate
• MitoQ (not a company): Mitoquinone - TPP-ubiquinone
• SS-31 (elamipretide): Mitochondria-targeted peptide

Mitophagy Inducers

Companies targeting the PINK1-PARKIN pathway to enhance clearance of damaged mitochondria:

• Vandria (VNA-100): Small molecule mitophagy activator

Catalytic Antioxidants

Companies using catalytic nanomaterials to support mitochondrial redox reactions:

• Clene Nanomedicine (CNM-Au8): Gold nanocrystals

CoQ10 Analogs and Precursors

Companies developing CoQ10 analogues for Complex I support:

• Mitothera (MT-101): Ubiquinone-based mitochondrial protectant
• Various nutraceutical companies

Clinical Pipeline Summary

| Company | Drug | Mechanism | Phase | Status |
|---------|------|-----------|-------|--------|
| NeuroMito | NMT-101 | Mitochondrial antioxidant | Phase 2 | Active |
| Clene | CNM-Au8 | Catalytic antioxidant | Phase 2 | Active |
| Napa | NP-101 | Mitochondria protectant | Phase 1 | Active |
| Vandria | VNA-100 | Mitophagy inducer | Preclinical | IND-enabling |
| Mitothera | MT-101 | CoQ10 analog | Preclinical | Research |

Scientific Rationale

Mitochondrial Dysfunction in PD

Mitochondrial dysfunction is one of the most consistent pathological findings in Parkinson's disease:

• Complex I deficiency: Observed in substantia nigra of sporadic PD patients
• Genetic evidence: PINK1, PARKIN, DJ-1 mutations cause familial PD through mitophagy defects
• Environmental evidence: MPTP, rotenone cause PD-like syndromes via Complex I inhibition
• Oxidative stress: Elevated ROS, reduced glutathione, increased lipid peroxidation

Therapeutic Target Rationale

Mitochondrial-targeted approaches offer several advantages:

Cross-References

• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [PINK1 Gene](/genes/pink1)
• [PARKIN Gene](/genes/parkin)
• [DJ-1 Gene](/genes/dj-1)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Neuroprotection](/mechanisms/neuroprotection-pathway)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Mitochondrial Antioxidants](/therapeutics/mitochondrial-antioxidants-neurodegeneration)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Neuroprotection](/treatments/neuroprotection)
• [Clinical Trials](/clinical-trials)

References